Chronic myeloid leukemia
Drug research and approvals for chronic myeloid leukemia: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 145 studies of chronic myeloid leukemia are recruiting on ClinicalTrials.gov, Health Canada has authorized 13 drug trials for it since 2013, and FDA has 15 approved and 13 open orphan designations naming it.
- Recruiting worldwide: 145
- Trials authorized in Canada: 13
- FDA orphan approvals: 15
- EU medicines: 0
- Phase 1 Study of 6MW5311 in Adults With Relapsed or Refractory Blood CancersNCT07914556 · Phase 1 · Mabwell (Shanghai) Bioscience Co., Ltd. · starts Sep 16, 2026
- A Study of ELVN-001 Versus Investigator-Selected TKI, in CP-CML Previously Treated With One or More TKIsNCT07905183 · Phase 3 · Enliven Therapeutics · starts Dec 31, 2026
- Efficacy of Asciminib in Chronic Phase CML Patients With T315I MutationsNCT07789574 · Phase 2 · Thomas Ernst, Prof. Dr. med. · starts Nov 1, 2026
- Low-dose Liposomal Amphotericin B for Antifungal Prophylaxis in Prolonged Neutropenia PatientsNCT07763054 · Not reported · Haikou Affiliated Hospital of Central South University Xiangya School of Medicine · starts Aug 1, 2025
- Allogeneic iNKT Cell Therapy (agenT-797) After SCTNCT07758218 · Phase 1 · University of Wisconsin, Madison · starts Nov 1, 2026
- Vididencel in CML-CP Patients With MRDNCT07651878 · Phase 1 · Mendus · starts Apr 14, 2026
- Impact of Targeted Therapy on Cancer-Related Cognitive ImpairmentNCT07638007 · Not reported · University of Rochester NCORP Research Base · starts Nov 21, 2025
- Thiotepa-Containing Conditioning Regimen for Allogeneic HSCT in Chronic Myelomonocytic LeukemiaNCT07588594 · Not applicable · Peking University People's Hospital · starts Feb 13, 2026
- Total Marrow and Lymphoid Irradiation in Combination With Fludarabine and Melphalan as Conditioning for Allogeneic…NCT07582172 · Phase 2 · City of Hope Medical Center · starts Nov 5, 2026
How its trials ended
979 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 315 whose ending is known, 37% met their primary endpoint, 3% missed it and 61% stopped early.
- Completed, result not reported39140%
- Ongoing17618%
- Met its primary endpoint11512%
- Stopped: other or unclear10411%
- Status unknown9710%
- Stopped: enrollment or feasibility566%
- Stopped: sponsor or business decision131%
- Missed its primary endpoint81%
- Stopped: lack of efficacy81%
- Stopped: funding71%
- Stopped: safety4<1%
| Apr 1, 2026 | A phase 1/2 clinical trial to evaluate the safety, tolerability, pharmacokinetics, and efficacy of TERN-701 in participants with chronic myeloid leukemiaTERN-701 | Terns Pharmaceuticals | Pending |
| Oct 26, 2023 | A phase 1a/1b study of ELVN-001 for the treatment of chronic myeloid leukemiaELVN-001 | Enliven Therapeutics | Ongoing |
| Jun 17, 2022 | A phase Ib study of the pharmacokinetics, safety and efficacy of orally administered HQP1351 in subjects with refractory chronic myeloid leukemia (CML) and…Olverembatinib (HQP1351) / Lisaftoclax (APG-2575) | Ascentage Pharma Group Inc. | Ongoing |
| Mar 8, 2021 | An open-label, multicentre, phase 1b/2 study of safety and efficacy of KRT-232 combined with a tyrosine kinase inhibitor (TKI) in patients with relapsed or…KRT-232 | Kartos Therapeutics Inc | Ongoing |
| Oct 8, 2015 | A randomized, open-label, phase 2 trial of ponatinib in patients with resistant chronic phase chronic myeloid leukemia to characterize the efficacy and safety…Ponatinib | Takeda Pharmaceuticals USA | Ongoing |
| Sep 3, 2015 | A randomized, open-label study of ponatinib versus nilotinib in patients with chronic myeloid leukemia in chronic phase following resistance to imatinibPonatinib | Ariad Pharmaceuticals | Closed |
| Jan 29, 2015 | A phase 3, multicenter, open-label, randomized study of SGI-110 versus treatment choice (TC) in adults with previously untreated acute myeloid leukemia (AML)…Guadecitabine (SGI-110)/ Cytarabine/ Azacitidine | Astex Pharmaceuticals Inc. | Closed |
| Sep 24, 2014 | Treatment-free remission accomplished with dasatinib in patients with CML.Dasatinib | University Health Network | Closed |
| Jul 25, 2014 | An open-label, single-group clinical study to evaluate the pharmacokinetics, safety, and efficacy of omacetaxine mepesuccinate given subcutaneously as a fixed…Synribo (omacetaxine) | Teva Pharmaceutical Industries | Pending |
| Nov 1, 2013 | A phase 1b dose escalation study to investigate the safety, tolerability and preliminary efficacy for the combination of dasatinib (BMS-354825) plus nivolumab…BMS-936558 (nivolumab) / BMS-354825 (dasatinib) | Bristol-Myers Squibb | Ongoing |
| May 29, 2026 | CavhanzaTreatment of adult patients with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase; and… | Cycle Pharmaceuticals Ltd | Approved |
| Aug 1, 2025 | PhyragoTreatment of pediatric patients 1 year of age and older with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in… | Handa Therapeutics, LLC | Approved |
| Nov 7, 2024 | DanzitenTreatment of adult patients with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase; and… | Azurity Pharmaceuticals, Inc. | Approved |
| Oct 29, 2024 | ScemblixTreatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP) | Novartis Pharmaceuticals Corporation | Approved |
| Oct 29, 2024 | ScemblixTreatment of adult patients with previously treated Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase… | Novartis Pharmaceuticals Corporation | Approved |
| Dec 5, 2023 | PhyragoTreatment of adult patients with: newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase;… | Handa Therapeutics, LLC | Approved |
| Oct 29, 2021 | ScemblixTreatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP) with the T315I… | Novartis Pharmaceuticals Corporation | Approved |
| Oct 29, 2021 | ScemblixTreatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP), previously… | Novartis Pharmaceuticals Corporation | Approved |
| Sep 23, 2021 | TasignaTreatment of pediatric patients greater than or equal to 1 year of age with chronic phase and accelerated phase Philadelphia chromosome… | Novartis Pharmaceuticals Corporation | Approved |
| Mar 22, 2018 | TasignaTASIGNA® (nilotinib) is indicated for the treatment of pediatric patients greater than or equal to 1 year of age with newly diagnosed… | Novartis Pharmaceuticals Corporation | Approved |
| Nov 9, 2017 | SprycelTreatment of pediatric patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase | Bristol-Myers Squibb Company | Approved |
| Dec 14, 2012 | IclusigTreatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) that is resistant or… | Takeda Pharmaceuticals U.S.A., Inc. | Approved |
| Oct 26, 2012 | SynriboTreatment of adult patients with chronic or accelerated phase chronic myeloid leukemia (CML) with resistance and/or intolerance to two or… | IVAX International GmbH | Approved |
| Jun 28, 2006 | SprycelTreatment of adults with chronic myeloid leukemia with resistance or intolerance to prior therapy including imatinib | Bristol-Myers Squibb Company | Approved |
| May 10, 2001 | GleevecTreatment of patients with chronic myeloid leukemia (CML) in blast crisis, accelerated phase, or in chronic phase after failure of… | Novartis Pharmaceuticals Corporation | Approved |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA